EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

SHR-A1811, a novel anti-HER2 antibody–drug conjugate with optimal drug-to-antibody ratio, efficient tumor killing potency, and favorable safety profiles

Ting Zhang, Jianyan Xu, Junzhao Yin, Yun Gao, Hanwen Zheng, Beibei Fu, Jiakang Sun, Zhibin Xu, Shiwei Tu, Yuchang Mao, Weiyun Wen, Bolei Qu und 7 weitere

PLOS One · 26.06.2025 · 20 (6) · e0326691

DOI: 10.1371/journal.pone.0326691 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS One, online erschienen am 26.06.2025. Verfasst von Ting Zhang und 18 weiteren Autor:innen. Beteiligte Einrichtung: Shanghai Hengrui Pharmaceutical Co., Ltd., Shanghai, China. Hauptthemen laut MEDLINE: Erb-b2 Receptor Tyrosine Kinases, Immunoconjugates, Trastuzumab. Die Arbeit wurde bisher 29-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Shanghai Hengrui Medicine.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

HER2-targeting antibody–drug conjugates (ADCs), especially trastuzumab deruxtecan (T-DXd), have revolutionized the treatment landscape of HER2-expressing or mutant cancers. However, undesired adverse events are still inevitable and it is necessary to discover a HER2-directed ADC with better safety profiles. SHR-A1811 is composed of trastuzumab, a cleavable linker and a novel topoisomerase I inhibitor, SHR169265. The results indicated that SHR169265 shows better permeability, strong cytotoxicity and faster systemic clearance than DXd analog (SHR197971). The drug-to-antibody ratio (DAR) of SHR-A1811 was optimized as 6 via balancing efficacy and toxicity. SHR-A1811 showed HER2-dependent growth inhibition against various cell lines and desirable bystander killing capability. SHR-A1811 led to tumor growth inhibition or even regression in a dose-dependent manner, at least comparable as HRA18-C015 (a synthesized T-DXd) and anti-HER2-SHR169265 (DAR 8) in multiple mouse xenograft models with a range of HER2 expression levels. SHR-A1811 exhibited a good pharmacokinetics profile, outstanding stability in plasma across different species and a favorable preclinical safety profile. The highest non-severely toxic dose (HNSTD) in cynomolgus monkeys was 40 mg/kg with thymus as the main target organ. The above results suggested that SHR-A1811 is a potential best-in-class anti-HER2 ADC with a highly permeable payload, optimized DAR, great potency and better safety profiles. Currently SHR-A1811 has entered phase II and phase III clinical studies for breast cancer, gastric cancer, colorectal cancer, and NSCLC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Erb-b2 Receptor Tyrosine KinasesImmunoconjugatesTrastuzumabAnimalsHumansMiceXenograft Model Antitumor AssaysCell Line, TumorFemaleAntibodies, Monoclonal, HumanizedRatsMice, Inbred BALB CMice, NudeCamptothecin

Substanzen

Erb-b2 Receptor Tyrosine KinasesImmunoconjugatesTrastuzumabAntibodies, Monoclonal, HumanizedCamptothecinERBB2 protein, humantrastuzumab deruxtecan

Autor:innen und Institutionen

  • Shanghai Hengrui Pharmaceutical Co., Ltd., Shanghai, China.
  • Shanghai Shengdi Pharmaceutical Co., Ltd., Shanghai, China.

ORCID-Profile: Min Hu

Förderung

  • Shanghai Hengrui Medicine

Zitieren

APA

Zhang, T., Xu, J., Yin, J., Gao, Y., Zheng, H., Fu, B., Sun, J., Xu, Z., Tu, S., Mao, Y., Wen, W., Qu, B., You, L., Xue, Z., Sun, X., Cao, D., Feng, J., Hu, M., & He, F. (2025). SHR-A1811, a novel anti-HER2 antibody–drug conjugate with optimal drug-to-antibody ratio, efficient tumor killing potency, and favorable safety profiles. PLOS One, 20(6), e0326691. https://doi.org/10.1371/journal.pone.0326691

Vancouver

Zhang T, Xu J, Yin J, Gao Y, Zheng H, Fu B, et al. SHR-A1811, a novel anti-HER2 antibody–drug conjugate with optimal drug-to-antibody ratio, efficient tumor killing potency, and favorable safety profiles. PLOS One. 2025;20(6):e0326691. doi:10.1371/journal.pone.0326691

BibTeX
@article{Zhang2025,
  author = {Zhang, Ting and Xu, Jianyan and Yin, Junzhao and Gao, Yun and Zheng, Hanwen and Fu, Beibei and Sun, Jiakang and Xu, Zhibin and Tu, Shiwei and Mao, Yuchang and Wen, Weiyun and Qu, Bolei and You, Lingfeng and Xue, Zhendong and Sun, Xing and Cao, Dan and Feng, Jun and Hu, Min and He, Feng},
  title = {SHR-A1811, a novel anti-HER2 antibody–drug conjugate with optimal drug-to-antibody ratio, efficient tumor killing potency, and favorable safety profiles},
  journal = {PLOS One},
  year = {2025},
  volume = {20},
  number = {6},
  pages = {e0326691},
  doi = {10.1371/journal.pone.0326691}
}
Kostenlos starten →